GLP-1 Drugs (Canada): 2025 Pulse Survey
The Pulse Survey: GLP-1 Drugs examines how Canadian employers are addressing coverage and policy decisions related to GLP-1 medications, traditionally used for diabetes management and weight loss. Survey results show that 31% of employers now cover GLP-1 drugs for both conditions—an increase from 17% in early 2024. Prior authorization and other utilization management strategies remain the primary tools for controlling costs.
There's more! View a full listing of International Foundation benchmarking and pulse survey reports.
Survey reports are just one of the many helpful products and services included with an International Foundation membership.